CEACAM6 and cancer: The binding partners of CEACAM6 are not well characterized, but it has been described to promote in vivo metastasis, tumor angiogenesis, vasculogenic mimicry in gastric cancer, and confers a poor prognosis to cancers overexpressing the protein [31].